Cognitive Impairment Associated With Schizophrenia (CIAS) Market Poised for Growth Due to Increasing Research into Novel Therapies



The cognitive impairment associated with schizophrenia (CIAS) market is comprised of medications and drugs that help address cognitive decline associated with schizophrenia. Cognitive deficits are a core feature of schizophrenia and involve impairments in various domains including attention, learning, memory, problem-solving and social cognition. These deficits severely impact day-to-day functioning and long-term prognosis of schizophrenia patients. The need for managing cognitive symptoms has been recognized with the revised diagnostic and statistical manual of mental disorders, 5th edition (DSM-5) criteria.


The global Cognitive Impairment Associated With Schizophrenia market is estimated to be valued at US$ 5.2 Bn in 2024 and is expected to exhibit a CAGR of 5.1% over the forecast period of 2024-2031.

Increased research into novel mechanisms and drug targets for treating cognitive dysfunction is one of the key factors driving the market. Over the past few years, there have been significant advances in understanding the biological underpinnings of cognitive impairments associated with schizophrenia including the role of glutamate dysfunction, inflammation and oxidative stress. This has paved way for developing new pharmacological interventions targeting these mechanisms.

Key Takeaways

Key players operating in the CIAS market are Boehringer Ingelheim International GmbH, Neurocrine Biosciences, Recognify Life Sciences, Atai Life Sciences, Kynexis.

The increasing prevalence of schizophrenia worldwide along with unmet need for managing cognitive symptoms present significant growth opportunities in the CIAS market. As per the WHO, over 21 million people suffer from schizophrenia globally. However, existing therapies approved for psychotic symptoms have shown limited efficacy in addressing cognitive impairments. This large untreated patient pool will drive the demand for cognitive enhancing drugs in the coming years.

Major players are actively pursuing regional and international expansion strategies to tap the emerging markets. For example, Neurocrine Biosciences has established commercial partnerships in China, Japan, Canada, Australia, Latin America and other regions to market Ingrezza, an FDA approved treatment for tardive dyskinesia with potential cognitive benefits. Atai Life Sciences is also building a pipeline of compounds targeting various cognitive domains through strategic partnerships in the USA and Europe.

Market Drivers

One of the key drivers of the CIAS market is increasing research funding for conditions like schizophrenia. Over the past decade, major public and private organizations like National Institutes of Health, Cures within Reach, and pharmaceutical companies have increased funding for schizophrenia related research. This has facilitated accelerated research into novel drug targets and biomarkers related to cognitive impairments. As of 2022, over US$ 140 million in public funding was committed for schizophrenia projects in the USA alone.

Market Restrains

High failure rate of drug trials is a major challenge restraining the growth of CIAS market. Drug development for cognitive disorders like schizophrenia is incredibly complex given incomplete understanding of disease pathology and variability in cognitive domains. As per industry estimates, over 95% of experimental drugs fail during clinical development due to lack of efficacy or safety issues. This increases the cost and R&D risks for companies, slowing the pace of new product introductions.


Segment Analysis
The Cognitive Impairment Associated with Schizophrenia (CIAS) market can be segmented based on disease type, therapeutic class, distribution channels, and geography. Within disease type, the positive symptom segment currently dominates due to a high proportion of CIAS patients experiencing positive symptoms such as hallucinations and delusions. Positive symptom drugs make up the majority of current prescriptions.

Within therapeutic class, the antipsychotics segment holds the largest share owing to widespread adoption of first-generation and second-generation antipsychotics for treating positive and negative symptoms. However, the therapies targeting cognitive deficits segment is expected to show high growth during the forecast period, driven by development of novel drugs directly targeting cognitive dysfunction.

Global Analysis
North America currently dominates the global CIAS market and is expected to continue its dominance during the forecast period. This can be attributed to growing awareness about cognitive impairment in schizophrenia, strong healthcare systems, and high prevalence of mental health disorders in the region. On the other hand, Asia Pacific is projected to witness the highest CAGR over the forecast period. Rapidly developing healthcare infrastructure and rising focus of global key players on expanding in emerging Asian countries are boosting the APAC CIAS market.

Get more insights on this topic : https://justpaste.it/c0mw5

What Are The Key Data Covered In This Cognitive Impairment Associated With Schizophrenia Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Cognitive Impairment Associated With Schizophrenia's growth between 2024 and 2031.

:- Accurate calculation of the size of the Cognitive Impairment Associated With Schizophrenia and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Cognitive Impairment Associated With Schizophrenia Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Cognitive Impairment Associated With Schizophrenia vendors

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it

Comments

Post a Comment

Popular posts from this blog

Laser Projection Market is to Witness High Growth Owing to Advancements in RGB Laser Projection Technology

Image
  The laser projection market involves the usage of laser diodes and phosphor wheels to project images instead of traditional light bulbs and rotating color wheels. Laser projection technology offers a variety of benefits over conventional projection including high brightness levels, long lifespan, high resolutions, and high contrast ratios. Laser projectors are increasingly being used for entertainment and commercial applications such as cinemas, digital signage, and conferences & seminars. The demand for   Laser Projection Market is driven by the superior image quality, higher resolutions and brighter images they provide compared to conventional projectors. The laser projection market is estimated to be valued at   USD 17.52 Bn in 2024   and is expected to reach   USD 56.28 Bn by 2031,  growing at a compound annual growth rate  (CAGR) of 18.1% from 2024 to 2031.  Key Takeaways Key players: Key players operating in the laser projection...
Read more

AL Amyloidosis Diagnostics is to Witness High Growth due to Advancements in Molecular Diagnostics and Flow Cytometry

Image
AL amyloidosis, also called primary (AL) amyloidosis, is a plasma cell disorder characterized by the buildup of abnormal protein deposits known as amyloid in tissues and organs. AL amyloidosis can affect the heart, kidneys, liver, nervous system, and digestive system. Early and precise diagnosis of AL Amyloidosis Diagnostics Market is very important for effective treatment and management of the disease. The AL amyloidosis diagnostic market is estimated to be valued at  USD 1.068 billion in 2024   and is expected to reach   USD 1.693 billion by 2031 , growing at a compound annual growth rate   (CAGR) of 6.8% from 2024 to 2031. Key Takeaways Key players operating in the AL amyloidosis diagnostics are Siemens Healthineers, Abbott Laboratories, IMMUNOConcepts, PrognostiX, Ark Diagnostics. The key opportunities in the AL amyloidosis diagnostics market include development of minimally invasive diagnostic techniques, adoption of PET imaging for diagnosis, advanceme...
Read more

Navigating the Stuttering Treatment Market: Top Solutions for Effective Speech Therapy

Image
The stuttering treatment market involves speech therapy techniques that help reduce or eliminate stuttering or stammering symptoms. Stuttering or stammering occurs when the flow of speech is disrupted by involuntary blocking, repetition, or prolongation of certain sounds. Such involuntary disruptions create difficulties in expressing thoughts fluently which can negatively impact an individual's self-confidence and social interactions. The need for effective Stuttering Market treatment solutions is rising due to the availability of advanced methods such as modified fluency shaping techniques, delayed auditory feedback devices, and self-therapy programs. The Global Stuttering Market is estimated to be valued at   USD 51.5 million in 2024   and is expected to reach   USD 150.1 million by 2031 , growing at a compound annual growth rate   (CAGR) of 11.3% from 2024 to 2031. Key Takeaways Key players operating in the stuttering treatment market are Johnson & Johns...
Read more